ECSP066992A - ACID 2 - {[2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL] AMINO} -3- (PHENYLPIRIDIN-2-ILAMINO) PROPERLY PURELY INHIBITOR OF THE IKB KINASE INHIBITOR - Google Patents

ACID 2 - {[2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL] AMINO} -3- (PHENYLPIRIDIN-2-ILAMINO) PROPERLY PURELY INHIBITOR OF THE IKB KINASE INHIBITOR

Info

Publication number
ECSP066992A
ECSP066992A EC2006006992A ECSP066992A ECSP066992A EC SP066992 A ECSP066992 A EC SP066992A EC 2006006992 A EC2006006992 A EC 2006006992A EC SP066992 A ECSP066992 A EC SP066992A EC SP066992 A ECSP066992 A EC SP066992A
Authority
EC
Ecuador
Prior art keywords
inhibitor
phenylpiridin
methylaminopirimidin
ilamino
indol
Prior art date
Application number
EC2006006992A
Other languages
Spanish (es)
Inventor
Olaf Ritzeler
El-Bdaoui Haddad
David John Aldous
Paul Joseph Cox
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP066992A publication Critical patent/ECSP066992A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida al compuesto sustancialmente puro de fórmula (A), (A)o una sal farmacéuticamente aceptable, o solvato de dicho compuesto; a una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz del compuesto de fórmula (A), y un vehículo farmacéuticamente aceptable; y al uso de un compuesto de fórmula (A) que tiene actividad como inhibidor, preferiblemente un inhibidor selectivo, de IkB (IKK), en particular IKK-2, y a métodos relacionados con ello.The present invention is directed to the substantially pure compound of formula (A), (A) or a pharmaceutically acceptable salt, or solvate of said compound; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (A), and a pharmaceutically acceptable carrier; and to the use of a compound of formula (A) having activity as an inhibitor, preferably a selective inhibitor, of IkB (IKK), in particular IKK-2, and related methods.

EC2006006992A 2004-05-12 2006-11-10 ACID 2 - {[2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL] AMINO} -3- (PHENYLPIRIDIN-2-ILAMINO) PROPERLY PURELY INHIBITOR OF THE IKB KINASE INHIBITOR ECSP066992A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12

Publications (1)

Publication Number Publication Date
ECSP066992A true ECSP066992A (en) 2006-12-29

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006992A ECSP066992A (en) 2004-05-12 2006-11-10 ACID 2 - {[2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL] AMINO} -3- (PHENYLPIRIDIN-2-ILAMINO) PROPERLY PURELY INHIBITOR OF THE IKB KINASE INHIBITOR

Country Status (23)

Country Link
EP (1) EP1747215A1 (en)
JP (1) JP2007537266A (en)
KR (1) KR20070011483A (en)
CN (1) CN1950359A (en)
AR (1) AR049274A1 (en)
AU (1) AU2005245834A1 (en)
BR (1) BRPI0511029A (en)
CA (1) CA2566213A1 (en)
EC (1) ECSP066992A (en)
GT (1) GT200500111A (en)
IL (1) IL178992A0 (en)
MA (1) MA28553B1 (en)
MX (1) MXPA06012870A (en)
NO (1) NO20065719L (en)
PA (1) PA8633101A1 (en)
PE (1) PE20060269A1 (en)
RU (1) RU2006143758A (en)
SV (1) SV2006002111A (en)
TN (1) TNSN06338A1 (en)
TW (1) TW200605881A (en)
UY (1) UY28897A1 (en)
WO (1) WO2005113544A1 (en)
ZA (1) ZA200608712B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (en) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
DE102004033406A1 (en) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Process for the preparation of the enantiomeric forms of 2,3-diaminopropionic acid derivatives
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
KR101449785B1 (en) 2008-04-21 2014-10-14 오토노미, 인코포레이티드 Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
KR20130069641A (en) * 2010-04-27 2013-06-26 허치슨 메디파르마 리미티드 Pyrimidinyl indole compounds
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP7033789B2 (en) 2016-06-29 2022-03-11 オトノミー,インク. Triglyceride ear preparation and its use
CN106588803A (en) * 2016-11-16 2017-04-26 西南科技大学 Novel method for preparing 5-acetylisoxazole

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase

Also Published As

Publication number Publication date
UY28897A1 (en) 2005-12-30
AR049274A1 (en) 2006-07-12
MA28553B1 (en) 2007-04-03
TW200605881A (en) 2006-02-16
BRPI0511029A (en) 2007-11-27
AU2005245834A1 (en) 2005-12-01
SV2006002111A (en) 2006-01-30
EP1747215A1 (en) 2007-01-31
RU2006143758A (en) 2008-06-27
GT200500111A (en) 2006-05-09
CA2566213A1 (en) 2005-12-11
IL178992A0 (en) 2007-03-08
NO20065719L (en) 2006-12-12
TNSN06338A1 (en) 2008-02-22
WO2005113544A1 (en) 2005-12-01
JP2007537266A (en) 2007-12-20
CN1950359A (en) 2007-04-18
KR20070011483A (en) 2007-01-24
MXPA06012870A (en) 2007-02-15
ZA200608712B (en) 2008-06-25
PE20060269A1 (en) 2006-05-11
PA8633101A1 (en) 2006-01-23

Similar Documents

Publication Publication Date Title
ECSP066992A (en) ACID 2 - {[2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL] AMINO} -3- (PHENYLPIRIDIN-2-ILAMINO) PROPERLY PURELY INHIBITOR OF THE IKB KINASE INHIBITOR
BRPI0408353A (en) compound, pharmaceutical composition, methods for the treatment of susceptible neoplasms and for the treatment of viral infections, and, use of a compound
AR062797A1 (en) PIPERIDINE DERIVATIVES AS RENINE INHIBITORS, PHARMACEUTICAL COMPOSITIONS.
EA200800670A1 (en) SERIOUS PROTEAS INHIBITORS
CO6231036A2 (en) SULFUR COMPOUNDS AS INHIBITORS OF THE SERINA PROTEASA NS3 OF THE HEPATITIS C VIRUS
EA200700192A1 (en) PHTHALASINE DERIVATIVES AS PARP INHIBITORS
CL2012001230A1 (en) Compounds derived from bicycles, inhibitors of the protein ns5a; pharmaceutical composition comprising them; use in the treatment of hepatitis c.
NO20091846L (en) Macrocyclic peptides as hepatitis C virus inhibitors
AR047076A1 (en) PIRROLOTRIAZINE COMPOUNDS AS THYROSINE KINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS
EA200701257A1 (en) PYRROPHORASOLES AS A STRONGLY-ACTING KINASE INHIBITORS
GT200600134A (en) NEW COMPOUNDS OF AMINOSULPHONYL DERIVATIVES
UY32062A (en) BETA-SECRETASA INHIBITORS
EA200900676A1 (en) HEPATITIS C VIRUS INHIBITORS
NO20091845L (en) Macrocyclic peptides such as hepatitis C virus inhibitors
AR056764A1 (en) USEFUL AMINOPIRIMIDINS AS QUINASE INHIBITORS
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
BRPI0507972A (en) compound, pharmaceutical composition, use of a compound, method for inhibiting the proteolytic activity of a postproline cleavage enzyme and packaged pharmaceutical composition
EA201200669A1 (en) PYRIDOPYRIMIDINONE INHIBITORS PI3Kα
NO20075616L (en) Tripeptides such as hepatitis C virus inhibitors
EA200970805A1 (en) SERINPROTEAS INHIBITORS FOR THE TREATMENT OF HCV INFECTIONS
ECSP088965A (en) 2-THIOXANTINE DERIVATIVES THAT ACT AS INHIBITORS OF THE MPO
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
EA200970041A1 (en) ACT INHIBITORS (PROTEIN KINASES B)
AR069098A1 (en) MACROCICLIC INHIBITORS OF THE NS3 SERINA PROTEASA OF THE HEPATITIS C VIRUS
AR091888A1 (en) UREA COMPOUNDS AND ITS USE AS ENZYMES INHIBITORS